《大行》里昂:和黃醫藥(00013.HK)賽沃替尼研究數據向好 維持「跑贏大市」評級
和黃醫藥(00013.HK)日前美國臨牀腫瘤學會(ASCO)年會上,公佈賽沃替尼(savolitinib)和奧希替尼(osimertinib)聯合療法用於治療非小細胞肺癌中國三期臨牀試驗的最新研究結果。里昂發表研報指,中期分析結果顯示,與對照組相比,賽沃替尼聯合奧希替尼的治療顯示出不俗療效及良好安全性,管理層提到總生存期趨勢向好但尚未成熟。
里昂預期,新研究數據應有利於賽沃替尼在中國的適應症擴展,維持和黃醫藥「跑贏大市」評級,及目標價30.7元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.